Bone metastases occur frequently in patients with advanced solid tumors and can create serious clinical problems that are commonly referred to as skeletal-related events.
Although bisphosphonates, especially zoledronic acid, have emerged as an integral determinant of managing metastatic bone disease, their application remains a challenge because of the lack of standardized measures and their side effects. Since factors derived from bone metabolism are potentially useful to measure the efficacy of zoledronic acid, several clinical trials have investigated these bone markers with respect to their monitoring values. The results suggest that a greater decline in bone marker levels is associated with a more reduced incidence of skeletal-related events and a better improvement of symptoms. This review summarizes the available evidence on the clinical use of bone markers in monitoring zoledronic acid in various cancers with bone metastases including breast, prostate and lung cancer.
Written by:
Huang Q, Ouyang X. Are you the author?
Department of Oncology, Fuzhou Genenal Hospital, Fujian - P.R. China.
Reference: Int J Biol Markers. 2013 May 7:0. Epub ahead of print.
doi: 10.5301/jbm.5000022
PubMed Abstract
PMID: 23661577
UroToday.com Prostate Cancer Section
